
สถิติโรคมะเร็ง โรงพยาบาลมะเร็งลำบาง ปี พ.ศ. 2567 (Hospital-Based Cancer Statistics, Lampang Cancer Hospital Annual Report 2024)







Lampang Cancer Hospital

June 2025 LPCH Cancer Registry Unit

ISBN: 978-616-11-5483-7



Foreword

Lampang Cancer Hospital (LPCH), under the Department of Medical Services, Ministry of Public Health, is committed to providing comprehensive cancer diagnosis, treatment, and cancer registration services for patients across Thailand's northern region. In alignment with our mission, LPCH has revised its strategic plan (2023–2027) to pursue the vision of becoming a high-performance cancer hospital, one that leverages advanced technology and medical innovation to improve the quality of life for the population. Our priorities also include fostering academic excellence, promoting knowledge transfer, and delivering integrated cancer care in collaboration with our regional healthcare partners.

In 2024, LPCH achieved several key milestones in quality assurance and institutional recognition. These include successful Quality Management Audits in Nuclear Medicine Practices (QUANUM) from the International Atomic Energy Agency (IAEA), a Pathology Laboratory Quality Audit endorsed by the Thai Society of Cytology, and laboratory accreditation from the Medical Technology Council. Additionally, the hospital attained the "Challenge Level" in the Green and Clean Hospital Challenge, reflecting our ongoing commitment to environmental health and sustainability.

LPCH continues to play a vital role in supporting Health Regions 1 and 2, not only through direct cancer care and referral services, but also in providing academic and clinical support. The performance improvements across the northern region are a testament to the dedication and collaboration of our hospital management team and healthcare personnel.

As we present the 2024 Hospital-Based Cancer Registry (HBCR) Annual Report, we reaffirm our commitment to enhancing the quality of cancer care in every dimension. We believe this report will serve as a valuable resource for healthcare professionals, researchers, and policymakers in driving forward our shared mission of improving the health and well-being of all Thai people.

(Dr. Rawin Ingsirorat)

Director of Lampang Cancer Hospital

Ron Ty



Preface

The hospital-based cancer registration (HBCR) is an integral component of the national cancer information system. In accordance with the Ministry of Public Health's policy, all A, S, and M1-level hospitals are required to establish cancer registries and submit hospital-based cancer registry (HBCR) reports. This initiative contributes to the development of a comprehensive national cancer registry and supports the publication of annual cancer statistics for Thailand.

Lampang Cancer Hospital (LPCH) established its hospital-based cancer registry in the year 2000 under the responsibility of the Cancer Registry Unit. Since its inception, the registry has prioritized the systematic collection of quality cancer data, adhering to international standards to ensure accuracy, completeness, and reliability.

This 2024 Cancer Statistics Annual Report is the 25th issue published by the LPCH hospital-based cancer registry. It presents data on newly diagnosed cancer cases among patients who received services at LPCH from January 1 to December 31, 2024. The report provides both an overall summary and detailed statistics on the seven most common cancers recorded during the year. This publication is the result of close collaboration among the Cancer Registry Unit and various departments across LPCH. We extend our sincere gratitude to the hospital's executive leadership for their continuous support and guidance in advancing the HBCR initiative. We hope that this report serves as a valuable resource for hospital administrators, healthcare providers, researchers, and policy makers. It is our goal that the information provided will support planning, quality improvement, and the ongoing development of cancer services at LPCH, while also contributing to the broader efforts of cancer control in Thailand.

Cancer Registry Unit Lampang Cancer Hospital

Contents

| Foreword | 1 |
|---|------|
| Preface | П |
| Faculty of providers | IV |
| Cancer diagnosis and treatment tools, Lampang Cancer Hospital | V |
| Process for Cancer Registry data collection | VII |
| Data visualization | VIII |
| Overview of new cancer patients in Lampang Cancer Hospital | 1 |
| 10 Leading new cancer patients in Lampang Cancer Hospital by Sex | 6 |
| 10 Leading new cancer patients in Lampang Cancer Hospital (Both Sex) | 7 |
| 7 Common Cancers in Lampang Cancer Hospital | 8 |
| (1) Head and Neck Cancer | 9 |
| (2) Colorectal Cancer | 12 |
| (3) Liver and bile duct Cancer | 15 |
| (4) Trachea, Bronchus, and lung Cancer | 18 |
| (5) Breast Cancer | 21 |
| (6) Cervical Cancer | 25 |
| (7) Thyroid Cancer | 29 |
| Number of new cancer by age and sex in Lampang Cancer Hospital (Male) | 32 |
| Number of new cancer by age and sex in Lampang Cancer Hospital (Female) | 33 |
| Pathology according to site and sex | 34 |
| Productivity of Cancer Registry, Lampang Cancer Hospital | 41 |

Functional Structure Cancer Registry Unit, LPCH

Advisory group



Dr. Rawin Ingsirorat
Director of Lampang Cancer Hospital



Dr. Tawarat Ruanrojrung Deputy Director for Health System Development



Dr. Pipat Kooprasertying
Deputy Director of Medical Services



Mrs. Sureerat Phuangsaijai Deputy Director for Nursing services



Mrs. Naranan Tarawat
Deputy Director for Administration



Mrs. Arada Pawong Head of Digital Medical Department

Staff



Mrs. Karnchana Daoprasert Registered Nurse Head of cancer registry unit



Ms. Ratchaneewan Chansawang Registered Nurse



Mrs. Kanniga Suksai Registered Nurse



Mrs. Sirinya Mahawat Statistician



Ms. Monthitinun Praditkay Statistician



Mr. Vorapat Muangsuwan Statistician



Mr.Pongsathon Kaewsimok Public Health Academic (Medical Statistician)



Mrs. Panida Suwanamuang General Service Officer

Contact:



https://www.lpch.go.th/canreg/



lampangregistry@gmail.com



054-335262-8 ต่อ 113



Hospital-Based Cancer Registry 2024 Lampang Cancer Hospital

Medical Equipment for Cancer diagnosis and treatment, Lampang Cancer Hospital

Radiotherapy

- 2012, Intensity Modulated Radiation Therapy Treatment Planning (IMRT Planning).
- 2013, Quality Assurance and Intra Treatment Verification.
- 2013, Linear Accelerator with Multi-Leaf Collimator (started using January 2014).
- 2016, Three Dimension for Intensity Moderated Radiotherapy Treatment Planning and Atlas-Based Organ Delineation lesion drawing program.
- 2017, The device determines the position and shape of the lesion and adjacent normal organs with a program to analyze changes in lesion size and normal organs between radiation therapy.
- 2017, High Energy Linear Accelerator with six degrees of freedom couch for SBRT and radiation oncology information system.
- 2018, Patient QA for Pre-Treatment QA.
- 2019, High Dose rate Control after loading with cobalt-60; 25 channel.
- 2019, High Energy Linear Accelerator with Image Guide.
- 2022, Superficial Hyperthermia.
- 2023, 4D Computed tomography simulator.
- 2024, Survey Meter for Radiation Leakage Detection



Volumetric Modulated Arc therapy (VMAT)



Intensity Modulated Radiotherapy Linear Accelerator

Medical Equipment for Cancer diagnosis and treatment, Lampang Cancer Hospital

Diagnostic Radiology

- 2010, Aplio MX Ultrasound
- 2013, Digital Subtraction/Flat Panel Detector; Model ZEXIRA
- 2016, Digital General x-ray
- 2016, Digital Mobile X-ray; Model SM-20HF-B-D-C
- 2018, Selenia Dimensions Digital Mammogram 2D and 3D
- 2019, Aplio i600 Ultrasound
- 2021, LOGIQ E10 Ultrasound
- 2021, Picture Archiving and Communication System and Radiology Information System (PACS & RIS)
- 2022, Aquilion Prime SP 160 Slice CT scanner
- 2023, Aplio i700 Prism Ultrasound


Nuclear Medicine

- 2016, Bone densitometer
- 2017, Thyroid uptake
- 2018, Single Photon Emission Computed Tomography/CT; SPECT/CT
- 2023, single Photon Emission Computed Tomography/CT: SPECT/CT



Single Photon Emission Computed Tomography/CT; SPECT/CT


Process for Hospital-Based Cancer Registry data collection



Hospital-Based Cancer Registry 2024










955 (35.8%) of new cancer cases



1,712 (64.2%) of new cancer cases

Top 5 Leading Cancer

Male



- 1. Prostate
- 2. Lung
- 3. Colorectal
- 4. Pharynx
- 5. Liver and bile duct

Female










- 1. Breast
- 2. Cervix uteri
- 3. Lung
- 4. Thyroid
- 5. Colorectal



Hospital-Based Cancer Registry 2024
Lampang Cancer Hospital

Hospital-Based Cancer Registry 2024





96% Histological proof

- Histology of primary
- Histology of metastasis
- Cytology and hematology

4% No histological proof

- Clinical investigation
- Surgery without histology




| ② | Radiotherapy | 36.7% |
|----------|------------------------------|-------|
| • | Concurrent RT | 17.0% |
| ② | Systemic therapy | 7.3% |
| | Chemotherapy | 6.5% |
| | Targeted therapy | 1.2% |
| | Immunotherapy | 0.1% |
| ② | Palliative care | 0.3% |
| ② | I-131 | 6.0% |
| ② | Surgery | 1.9% |
| ② | Hormone | 0.3% |
| ② | Consult/Investigation | 33.6% |
| | Note: Investigation = CT/Bor | ne. |

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan

New cancer patients in Lampang Cancer Hospital, 2024


All new cancer patients undergoing service in Lampang Cancer Hospital in 2024 have 2,667 cases (34.3% of all new cases and 3.6% of all outpatients). In addition, the number of new cancer patients in 2024 increased from 2015 by 12.8%



| Cases | Number | Percentage (%) |
|--|--------|---|
| Number of all outpatients | 74,573 | 100.0 |
| Number of all new cases (Checkup, cancer cases and other disease) | 7,779 | 10.43 |
| Number of new cancer cases | 2,667 | 3.6 (of all outpatients) 34.3 (of all new cases) |

New cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group | Ма | le | Fem | ale | Both | ı sex |
|-----------|-----|------|-------|------|-------|-------|
| (Year) | N | % | N | % | N | % |
| 0 - 4 | 1 | 0.0 | 0 | 0.0 | 1 | 0.0 |
| 5 - 9 | 2 | 0.1 | 0 | 0.0 | 2 | 0.1 |
| 10 - 14 | 3 | 0.1 | 0 | 0.0 | 3 | 0.1 |
| 15 - 19 | 5 | 0.2 | 3 | 0.1 | 8 | 0.3 |
| 20 - 24 | 4 | 0.1 | 7 | 0.3 | 11 | 0.4 |
| 25 - 29 | 4 | 0.1 | 22 | 0.8 | 26 | 1.0 |
| 30 - 34 | 7 | 0.3 | 51 | 1.9 | 58 | 2.2 |
| 35 - 39 | 16 | 0.6 | 87 | 3.3 | 103 | 3.9 |
| 40 - 44 | 22 | 0.8 | 121 | 4.5 | 143 | 5.4 |
| 45 - 49 | 28 | 1.0 | 173 | 6.5 | 201 | 7.5 |
| 50 - 54 | 83 | 3.1 | 231 | 8.7 | 314 | 11.8 |
| 55 - 59 | 111 | 4.2 | 287 | 10.8 | 398 | 14.9 |
| 60 - 64 | 182 | 6.8 | 260 | 9.7 | 442 | 16.6 |
| 65 - 69 | 170 | 6.4 | 210 | 7.9 | 380 | 14.2 |
| 70 - 74 | 164 | 6.1 | 152 | 5.7 | 316 | 11.8 |
| 75 - 79 | 100 | 3.7 | 69 | 2.6 | 169 | 6.3 |
| 80 - 84 | 35 | 1.3 | 27 | 1.0 | 62 | 2.3 |
| 85 + | 18 | 0.7 | 12 | 0.4 | 30 | 1.1 |
| Total | 955 | 35.8 | 1,712 | 64.2 | 2,667 | 100.0 |



Location of new cancer patients in Lampang Cancer Hospital, 2024


| Bussians | Ma | ale | Fen | nale | Total | | |
|---------------------|-----|-------|-------|-------|-------|--------|--|
| Provinces | N | % | N | % | N | % | |
| Lampang | 328 | 12.30 | 395 | 14.81 | 723 | 27.11 | |
| Chiang Rai | 151 | 5.66 | 333 | 12.49 | 484 | 18.15 | |
| Phrae | 120 | 4.50 | 224 | 8.40 | 344 | 12.90 | |
| Phayao | 113 | 4.24 | 181 | 6.79 | 294 | 11.02 | |
| Nan | 88 | 3.30 | 146 | 5.47 | 234 | 8.77 | |
| Chiang Mai | 36 | 1.35 | 167 | 6.26 | 203 | 7.61 | |
| Uttaradit | 40 | 1.50 | 78 | 2.92 | 118 | 4.42 | |
| Lamphun | 18 | 0.67 | 87 | 3.26 | 105 | 3.94 | |
| Tak | 25 | 0.94 | 35 | 1.31 | 60 | 2.25 | |
| Sukhothai | 20 | 0.75 | 26 | 0.97 | 46 | 1.72 | |
| Kamphaeng Phet | 7 | 0.26 | 7 | 0.26 | 14 | 0.52 | |
| Mae Hong Son | 2 | 0.07 | 9 | 0.34 | 11 | 0.41 | |
| Phitsanulok | 2 | 0.07 | 7 | 0.26 | 9 | 0.34 | |
| Bangkok | 1 | 0.04 | 3 | 0.11 | 4 | 0.15 | |
| Loei | 0 | 0.00 | 2 | 0.07 | 2 | 0.07 | |
| Chaiyaphum | 0 | 0.00 | 1 | 0.04 | 2 | 0.07 | |
| Phetchaburi | 0 | 0.00 | 2 | 0.07 | 1 | 0.04 | |
| Phetchabun | 0 | 0.00 | 1 | 0.04 | 1 | 0.04 | |
| Chainat | 0 | 0.00 | 1 | 0.04 | 1 | 0.04 | |
| Nakhon Ratchasima | 0 | 0.00 | 1 | 0.04 | 1 | 0.04 | |
| Nakhon Sawan | 0 | 0.00 | 1 | 0.04 | 1 | 0.04 | |
| Nonthaburi | 1 | 0.04 | 1 | 0.04 | 1 | 0.04 | |
| Pathum Thani | 0 | 0.00 | 0 | 0.00 | 1 | 0.04 | |
| Prachuap Khiri Khan | 1 | 0.04 | 1 | 0.04 | 1 | 0.04 | |
| Pattani | 1 | 0.04 | 0 | 0.00 | 1 | 0.04 | |
| Yasothon | 0 | 0.00 | 0 | 0.00 | 1 | 0.04 | |
| Yala | 0 | 0.00 | 1 | 0.04 | 1 | 0.04 | |
| Ratchaburi | 1 | 0.04 | 1 | 0.04 | 1 | 0.04 | |
| Laos | 0 | 0.00 | 0 | 0.00 | 1 | 0.04 | |
| Myanmar | 0 | 0.00 | 1 | 0.04 | 1 | 0.04 | |
| Total | 955 | 35.81 | 1,712 | 64.19 | 2,667 | 100.00 | |



Note: Other provinces were Kamphaeng Phet, Bangkok, Loei, Chaiyaphum, Phetchaburi, Chainat, Nakhon Ratchasima, Nakhon Sawan, Nonthaburi, Pathum Thani, Prachuap Khiri Khan, Pattani, Yasothon, Yala, Ratchaburi, Laos, and Myanmar


Number and Percentage of Histological verified since 2015 - 2024

| Year | Number of new cancer cases | Number of histological verified | Percentage |
|------|----------------------------------|---------------------------------------|------------|
| 2015 | 2,583 | 2,331 | 90.24 |
| 2016 | 2,487 | 2,180 | 87.66 |
| 2017 | 2,290 | 2,018 | 88.12 |
| 2018 | 2,207 | 1,973 | 89.40 |
| 2019 | 2,426 | 2,169 | 89.41 |
| 2020 | 2,690 | 2,415 | 89.78 |
| 2021 | 2,646 | 2,475 | 93.54 |
| 2022 | 2,713 | 2,542 | 93.73 |
| 2023 | 2,902 | 2,739 | 94.38 |
| 2024 | 2,667 | 2,571 | 96.40 |




Tpye of Diagnosis, 2024

| Type of Diagnosis | Male | Female | Total | Percentage |
|---|------|--------|-------|------------|
| Histological proof | 899 | 1,672 | 2,571 | 96.40 |
| Histology of primary | 825 | 1,594 | 2,419 | 90.70 |
| Histology of metastasis | 60 | 61 | 125 | 4.54 |
| Cytology and hematology | 14 | 17 | 31 | 1.16 |
| No histological proof | 56 | 40 | 96 | 3.60 |
| Clinical investigation | 53 | 38 | 91 | 3.45 |
| Surgery without histology | 2 | 1 | 3 | 0.15 |
| Total | 995 | 1,712 | 2,667 | 100.00 |



Staging of new cancer patients in Lampang Cancer Hospital, 2024




Extension of new cancer patients in Lampang Cancer Hospital, 2024

| Extension | Male | Female | Total | % |
|---------------------|------|--------|-------|-------|
| Localized | 84 | 412 | 496 | 18.6 |
| Direct extension | 71 | 111 | 182 | 6.8 |
| Regional lymph node | 224 | 715 | 939 | 35.2 |
| Distant metastasis | 387 | 380 | 767 | 28.8 |
| Not applicable | 14 | 12 | 27 | 1.0 |
| Not known | 175 | 80 | 256 | 9.6 |
| Total | 955 | 1,712 | 2,667 | 100.0 |
| | | | | |
| | | | | N |
| | | | | IN |

Metastasis sites in stage IV. 2024


| Metastasis site | Male | Female | Total | % |
|--------------------|------|--------|-------|-------|
| Distant lymph node | 52 | 90 | 142 | 18.5 |
| Bone | 104 | 59 | 163 | 21.3 |
| Liver | 33 | 15 | 48 | 6.3 |
| Lung/Pleura | 42 | 45 | 88 | 11.3 |
| Brain | 29 | 39 | 68 | 8.9 |
| Peritoneum | 2 | 4 | 6 | 8.0 |
| Other | 9 | 5 | 13 | 1.8 |
| Multiple sites | 115 | 123 | 238 | 31.0 |
| Not known site | 1 | 0 | 1 | 0.1 |
| Total | 387 | 380 | 767 | 100.0 |




Type of treatment in Lampang Cancer Hospital, 2024

| Treatmemt | Male | Female | Total | % |
|--------------------------------------|------|--------|-------|-------|
| Surgery | 9 | 43 | 52 | 1.95 |
| Radiotherapy | 300 | 678 | 978 | 36.67 |
| Systemic therapy | 86 | 109 | 195 | 7.31 |
| Chemotherapy | 75 | 98 | 173 | 6.49 |
| Targeted Therapy | 15 | 18 | 33 | 1.24 |
| Immunotherapy | 2 | 2 | 4 | 0.15 |
| Concurrent RT | 189 | 264 | 453 | 16.99 |
| I-131 | 28 | 131 | 159 | 5.96 |
| Palliative care | 3 | 6 | 9 | 0.34 |
| Hormone | 2 | 5 | 7 | 0.26 |
| Consult/Investigation | 357 | 538 | 895 | 33.56 |
| Investigation | 245 | 442 | 687 | 25.76 |
| Consult | 112 | 94 | 206 | 7.72 |

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




10 Leading new cancer patients in Lampang Cancer Hospital by Sex. 2024



| | Male | | |
|--------|-----------------------------------|--------|------|
| Rating | Cancer sites | Number | % |
| 1 | C61 Prostate | 240 | 25.1 |
| 2 | C33-34 Trachea, Bronchus and lung | 153 | 16.0 |
| 3 | C18-20 Colorectal | 153 | 16.0 |
| 4 | C09-14 Pharynx | 77 | 8.1 |
| 5 | C22,C24 Liver and bile duct | 64 | 6.7 |
| 6 | C15 Oesophagus | 35 | 3.7 |
| 7 | C00-06 Oral cavity | 31 | 3.2 |
| 8 | C73 Thyroid | 30 | 3.1 |
| 9 | C32 Larynx | 26 | 2.7 |
| 10 | C81-86,C88,C96 Lymphoma | 25 | 2.6 |

| | Female | | |
|--------|-----------------------------------|--------|------|
| Rating | Cancer sites | Number | % |
| 1 | C50 Breast | 806 | 47.1 |
| 2 | C53 Cervix | 231 | 13.5 |
| 3 | C73 Thyroid | 138 | 8.1 |
| 4 | C33-34 Trachea, Bronchus and lung | 128 | 7.5 |
| 5 | C18-20 Colorectal | 109 | 6.4 |
| 6 | C54 Corpus Uteri | 105 | 6.1 |
| 7 | C22,C24 Liver and bile duct | 22 | 1.3 |
| 8 | C09-14 Pharynx | 23 | 1.3 |
| 9 | C00-06 Oral cavity | 19 | 1.1 |
| 10 | C81-86,C88,C96 Lymphoma | 19 | 1.1 |

10 Leading new cancer patients in Lampang Cancer Hospital (Both sex), 2024




| Rating | Cancer sites | Number | Percentage |
|--------|-----------------------------------|--------|------------|
| 1 | C50 Breast | 810 | 30.4 |
| 2 | C33-34 Trachea, Bronchus and lung | 281 | 10.5 |
| 3 | C18-20 Colorectal | 262 | 9.8 |
| 4 | C61 Prostate | 240 | 9.0 |
| 5 | C53 Cervix | 231 | 8.7 |
| 6 | C73 Thyroid | 168 | 6.3 |
| 7 | C54 Corpus Uteri | 105 | 3.9 |
| 8 | C09-14 Pharynx | 100 | 3.7 |
| 9 | C22,C24 Liver and bile duct | 86 | 3.2 |
| 10 | C00-06 Oral cavity | 50 | 1.9 |




Head and Neck Cancer ICD-0: C00-14, C30-32

Trend of new head and neck cancer patients in Lampang Cancer Hospital 10 years (since 2015 - 2024)




Number of new head and neck cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group | Ma | le | Fem | ale | Botl | n sex |
|-----------|-----|------|-----|------|------|-------|
| (Year) | N | % | N | % | N | % |
| 20 - 24 | 1 | 0.5 | 0 | 0.0 | 1 | 0.5 |
| 25 - 29 | 1 | 0.5 | 0 | 0.0 | 1 | 0.5 |
| 30 - 34 | 2 | 1.0 | 1 | 0.5 | 3 | 1.5 |
| 35 - 39 | 3 | 1.5 | 2 | 1.0 | 5 | 2.5 |
| 40 - 44 | 9 | 4.6 | 5 | 2.5 | 14 | 7.1 |
| 45 - 49 | 7 | 3.6 | 5 | 2.5 | 12 | 6.1 |
| 50 - 54 | 21 | 10.7 | 11 | 5.6 | 32 | 16.2 |
| 55 - 59 | 22 | 11.2 | 9 | 4.6 | 31 | 15.7 |
| 60 - 64 | 36 | 18.3 | 2 | 1.0 | 38 | 19.3 |
| 65 - 69 | 17 | 8.6 | 6 | 3.0 | 23 | 11.7 |
| 70 - 74 | 12 | 6.1 | 2 | 1.0 | 14 | 7.1 |
| 75 - 79 | 7 | 3.6 | 5 | 2.5 | 12 | 6.1 |
| 80 - 84 | 4 | 2.0 | 2 | 1.0 | 6 | 3.0 |
| 85+ | 3 | 1.5 | 2 | 1.0 | 5 | 2.5 |
| Total | 145 | 73.6 | 52 | 26.4 | 197 | 100.0 |



Type of diagnosis of new head and neck cancer patients in Lampang Cancer Hospital, 2023


| Type of Diagnosis | Male | Female | Total | % |
|-------------------------|------|--------|-------|--------|
| Clinical investigation | 1 | 1 | 2 | 1.02 |
| Cytology and hematology | 1 | 0 | 1 | 0.50 |
| Histology of metastasis | 1 | 1 | 2 | 1.02 |
| Histology of primary | 142 | 50 | 192 | 97.46 |
| Total | 145 | 52 | 197 | 100.00 |



Treatment of new head and neck cancer patients in Lampang Cancer Hospital, 2024


| Type of treatment | Male | Female | Total | % |
|-----------------------------------|------|--------|-------|-------|
| Radiotherapy | 48 | 14 | 62 | 31.47 |
| Systemic therapy | | | | |
| Chemotherapy | 5 | 3 | 8 | 4.06 |
| Concurrent RT | 67 | 25 | 92 | 46.70 |
| Consult/Investigation | | | | |
| Investigation | 8 | 6 | 14 | 7.11 |
| Consult | 19 | 6 | 25 | 12.69 |

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new head and neck cancer patients in Lampang Cancer Hospital, 2024

| Staging | Male | Female | Total | % |
|---------------|------|--------|-------|--------|
| Stage I | 13 | 1 | 14 | 7.11 |
| Stage II | 11 | 7 | 18 | 9.14 |
| Stage III | 26 | 9 | 35 | 17.77 |
| Stage IV | 87 | 30 | 117 | 59.39 |
| Unknown Stage | 8 | 5 | 13 | 6.60 |
| Total | 145 | 52 | 197 | 100.00 |




Extension of new head and neck cancer patients in Lampang Cancer Hospital, 2024



Metastasis sites of new head and neck cancer patients in Lampang Cancer Hospital. 2024


| Extension | Male | Female | Total | % |
|--------------------|------|--------|-------|-------|
| Distant lymph node | 5 | 1 | 6 | 24.0 |
| Bone | 3 | 0 | 3 | 12.0 |
| Liver | 3 | 1 | 4 | 16.0 |
| Lung/Pleura | 2 | 2 | 4 | 16.0 |
| Brain | 1 | 1 | 2 | 8.0 |
| Other | 1 | 0 | 1 | 4.0 |
| Multiple sites | 4 | 1 | 5 | 20.0 |
| Total | 19 | 6 | 25 | 100.0 |



Hospital-Based Cancer Registry 2024 Lampang Cancer Hospital


Colorectal Cancer ICD-0: C18-20

Trend of new colorectal cancer patients in Lampang Cancer Hospital 20 years (since 2005 - 2024)




Number of new colorectal cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group | Ма | ile | Female | | Botl | ı sex |
|-----------|-----|------|--------|------|------|-------|
| (Year) | N | % | N | % | N | % |
| 25-29 | 1 | 0.4 | 2 | 0.8 | 3 | 1.1 |
| 30-34 | 2 | 0.8 | 0 | 0.0 | 2 | 0.8 |
| 35-39 | 1 | 0.4 | 3 | 1.1 | 4 | 1.5 |
| 40-44 | 3 | 1.1 | 2 | 0.8 | 5 | 1.9 |
| 45-49 | 6 | 2.3 | 5 | 1.9 | 11 | 4.2 |
| 50-54 | 16 | 6.1 | 10 | 3.8 | 26 | 9.9 |
| 55-59 | 21 | 8.0 | 22 | 8.4 | 43 | 16.4 |
| 60-64 | 25 | 9.5 | 25 | 9.5 | 50 | 19.1 |
| 65-69 | 34 | 13.0 | 20 | 7.6 | 54 | 20.6 |
| 70-74 | 25 | 9.5 | 12 | 4.6 | 37 | 14.1 |
| 75-79 | 11 | 4.2 | 4 | 1.5 | 15 | 5.7 |
| 80-84 | 5 | 1.9 | 3 | 1.1 | 8 | 3.1 |
| 85+ | 3 | 1.1 | 1 | 0.4 | 4 | 1.5 |
| Total | 153 | 58.4 | 109 | 44.3 | 262 | 100.0 |




Type of diagnosis of new colorectal cancer patients in Lampang Cancer Hospital, 2024

| Type of Diagnosis | Male | Female | Total | % |
|--|------|--------|-------|--------|
| Clinical investigation | 2 | 2 | 4 | 1.53 |
| Histology of metastasis | 2 | 1 | 3 | 1.15 |
| Histology of primary | 149 | 106 | 255 | 97.33 |
| Total | 153 | 109 | 262 | 100.00 |



Treatment of new colorectal cancer patients in Lampang Cancer Hospital, 2024


| Type of treatment | Male | Female | Total | % |
|-----------------------------------|------|--------|-------|-------|
| Surgery | 5 | 6 | 11 | 4.20 |
| Radiotherapy | 36 | 21 | 57 | 21.76 |
| Systemic therapy | | | | |
| Chemotherapy | 11 | 11 | 22 | 8.40 |
| Targetd Therapy | 3 | 1 | 4 | 1.53 |
| Concurrent RT | 82 | 58 | 140 | 53.44 |
| Palliative care | 0 | 2 | 2 | 0.76 |
| Consult/Investigation | | | | |
| Investigation | 9 | 5 | 14 | 5.34 |
| Consult | 15 | 9 | 24 | 9.16 |




Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan

Staging of new colorectal cancer patients in Lampang Cancer Hospital, 2024

| Staging | Male | Female | Total | % |
|---------------|------|--------|-------|--------|
| Stage I | 8 | 2 | 10 | 3.82 |
| Stage II | 21 | 19 | 40 | 15.27 |
| Stage III | 73 | 46 | 119 | 45.42 |
| Stage IV | 44 | 33 | 77 | 29.39 |
| Unknown Stage | 7 | 9 | 16 | 6.11 |
| Total | 153 | 109 | 262 | 100.00 |




Extension of new colorectal cancer patients in Lampang Cancer Hospital, 2024



Metastasis sites of new colorectal cancer patients in Lampang Cancer Hospital, 2024


| Extension | Male | Female | Total | % |
|--------------------|------|--------|-------|--------|
| Distant lymph node | 3 | 4 | 7 | 9.33 |
| Bone | 4 | 1 | 5 | 6.67 |
| Liver | 12 | 4 | 16 | 21.33 |
| Lung/Pleura | 3 | 5 | 8 | 10.67 |
| Brain | 1 | 0 | 1 | 1.33 |
| Peritoneum | 1 | 1 | 2 | 2.67 |
| Multiple sites | 16 | 17 | 34 | 45.33 |
| Other | 3 | 0 | 2 | 2.67 |
| Total | 43 | 32 | 75 | 100.00 |



Hospital-Based Cancer Registry 2024 Lampang Cancer Hospital


Liver and bile ducts Cancer ICD-0: C22, C24

Trend of new liver and bile ducts cancer patients in Lampang Cancer Hospital 20 years (since 2005 - 2024)




Number of new liver and bile ducts cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group | Male | | Female | | Bot | h sex |
|-----------|------|-------|--------|-------|-----|--------|
| (Year) | N | % | N | % | N | % |
| 10-14 | 1 | 1.16 | 0 | 0.00 | 1 | 1.16 |
| 15-19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20-24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25-29 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 30-34 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 35-39 | 1 | 1.16 | 0 | 0.00 | 1 | 1.16 |
| 40-44 | 0 | 0.00 | 1 | 1.16 | 1 | 1.16 |
| 45-49 | 2 | 2.33 | 1 | 1.16 | 3 | 3.49 |
| 50-54 | 4 | 4.65 | 0 | 0.00 | 4 | 4.65 |
| 55-59 | 11 | 12.79 | 2 | 2.33 | 13 | 15.12 |
| 60-64 | 23 | 26.74 | 5 | 5.81 | 28 | 32.56 |
| 65-69 | 9 | 10.47 | 7 | 8.14 | 16 | 18.60 |
| 70-74 | 9 | 10.47 | 6 | 6.98 | 15 | 17.44 |
| 75-79 | 4 | 4.65 | 0 | 0.00 | 4 | 4.65 |
| Total | 64 | 74.42 | 22 | 25.58 | 86 | 100.00 |




Type of diagnosis of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2024


| Type of Diagnosis | Male | Female | Total | % |
|-------------------------|------|--------|-------|--------|
| Clinical investigation | 33 | 9 | 42 | 48.84 |
| Cytology and hematology | 0 | 1 | 1 | 1.16 |
| Histology of metastasis | 3 | 3 | 6 | 6.98 |
| Histology of primary | 28 | 9 | 37 | 43.02 |
| Total | 64 | 22 | 86 | 100.00 |



Treatment of new liver and bile ducts cancer patients in Lampang Cancer Hospital. 2024


| Type of treatment | Male | Female | Total | % |
|-------------------------------------|------|--------|-------|-------|
| Radiotherapy | 16 | 7 | 23 | 26.74 |
| Systemic therapy | | | | |
| Chemotherapy | 13 | 6 | 19 | 22.09 |
| Targetd Therapy | 4 | 1 | 5 | 5.81 |
| Immonotherapy | 2 | 1 | 3 | 3.49 |
| Concurrent RT | 2 | 2 | 4 | 4.65 |
| Palliative care | 1 | 0 | 1 | 1.16 |
| Consult/Investigation | | | | |
| Investigation | 8 | 1 | 9 | 10.47 |
| Consult | 19 | 6 | 25 | 29.07 |







Staging of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2024

| Staging | Male | Female | Total | % |
|---------------|------|--------|-------|--------|
| Stage I | 0 | 1 | 1 | 1.16 |
| Stage II | 1 | 1 | 2 | 2.33 |
| Stage III | 2 | 1 | 3 | 3.49 |
| Stage IV | 44 | 17 | 61 | 70.93 |
| Unknown Stage | 17 | 2 | 19 | 22.09 |
| Total | 64 | 22 | 86 | 100.00 |




Extension of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2024






Metastasis sites of new liver and bile ducts cancer patients in Lampang Cancer Hospital, 2024

| | Extension | Male | Female | Total | % |
|---|--------------------|------|--------|-------|--------|
| | Distant lymph node | 7 | 2 | 9 | 15.00 |
| | Bone | 5 | 2 | 7 | 11.67 |
| | Liver | 6 | 1 | 7 | 11.67 |
| | Lung/Pleura | 6 | 2 | 8 | 13.33 |
| | Brain | 1 | 2 | 3 | 5.00 |
| 0 | Other | 1 | 0 | 1 | 1.67 |
| | Multiple sites | 18 | 7 | 25 | 41.67 |
| | Total | 44 | 16 | 60 | 100.00 |




Lung Cancer ICD-0: C33 - 34

Trend of new lung cancer patients in Lampang Cancer Hospital 20 years (since 2005 - 2024)




Number of new lung cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group Male | | le | Female | | Both sex | |
|----------------|-----|------|--------|------|----------|-------|
| (Year) | N | % | N | % | N | % |
| 25-29 | 0 | 0.0 | 1 | 0.4 | 1 | 0.4 |
| 30-34 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 35-39 | 0 | 0.0 | 2 | 0.7 | 2 | 0.7 |
| 40-44 | 3 | 1.1 | 2 | 0.7 | 5 | 1.8 |
| 45-49 | 7 | 2.5 | 5 | 1.8 | 12 | 4.3 |
| 50-54 | 15 | 5.3 | 14 | 5.0 | 29 | 10.3 |
| 55-59 | 15 | 5.3 | 25 | 8.9 | 40 | 14.2 |
| 60-64 | 42 | 14.9 | 24 | 8.5 | 66 | 23.4 |
| 65-69 | 29 | 10.6 | 19 | 6.7 | 48 | 17.1 |
| 70-74 | 29 | 10.3 | 24 | 8.5 | 53 | 18.9 |
| 75-79 | 9 | 3.2 | 10 | 3.5 | 19 | 6.8 |
| 80-84 | 3 | 1.1 | 2 | 0.7 | 5 | 1.8 |
| 85+ | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 |
| Total | 153 | 54.6 | 128 | 45.4 | 281 | 100.0 |




Type of diagnosis of new lung cancer patients in Lampang Cancer Hospital, 2024


| Type of Diagnosis | Male | Female | Total | % |
|-------------------------|------|--------|-------|--------|
| Clinical investigation | 13 | 18 | 31 | 11.03 |
| Cytology and hematology | 11 | 9 | 20 | 7.12 |
| Histology of metastasis | 38 | 33 | 71 | 25.27 |
| Histology of primary | 91 | 68 | 159 | 56.58 |
| Total | 153 | 128 | 281 | 100.00 |



Treatment of new lung cancer patients in Lampang Cancer Hospital, 2024


| Type of treatment | Male | Female | Total | % |
|-------------------------------------|------|--------|-------|-------|
| Radiotherapy | 69 | 60 | 129 | 45.91 |
| Systemic therapy | | | | |
| Chemotherapy | 19 | 22 | 41 | 14.59 |
| Targetd Therapy | 6 | 11 | 17 | 6.05 |
| Concurrent RT | 2 | 0 | 2 | 0.71 |
| Palliative care | 0 | 1 | 1 | 0.36 |
| Consult/Investigation | | | | |
| Investigation | 13 | 7 | 20 | 7.12 |
| Consult | 10 | 10 | 20 | 7.12 |






Staging of new lung cancer patients in Lampang Cancer Hospital, 2024

| Staging | Male | Female | Total | % |
|---------------|------|--------|-------|--------|
| Stage I | 5 | 2 | 7 | 2.49 |
| Stage II | 3 | 2 | 5 | 1.78 |
| Stage III | 26 | 15 | 41 | 14.59 |
| Stage IV | 115 | 102 | 217 | 77.22 |
| Unknown Stage | 4 | 7 | 11 | 3.91 |
| Total | 153 | 128 | 281 | 100.00 |




Extension of new lung cancer patients in Lampang Cancer Hospital, 2024

| Extension | Male | Female | Total | % |
|---------------------|------|--------|-------|--------|
| Localized | 6 | 3 | 9 | 3.20 |
| Direct extension | 5 | 3 | 8 | 2.85 |
| Regional lymph node | 23 | 15 | 38 | 13.52 |
| Distant metastasis | 115 | 100 | 215 | 76.51 |
| Not known | 4 | 7 | 11 | 3.91 |
| Total | 153 | 128 | 281 | 100.00 |




Metastasis sites of new lung cancer patient in Lampang Cancer Hospital, 2024

| Extension | Male | Female | Total | % |
|--------------------|------|--------|-------|--------|
| Distant lymph node | 10 | 5 | 15 | 6.98 |
| Bone | 14 | 12 | 26 | 12.09 |
| Liver | 2 | 1 | 3 | 1.40 |
| Lung/Pleura | 14 | 14 | 28 | 13.02 |
| Brain | 25 | 28 | 53 | 24.65 |
| Other | 1 | 1 | 2 | 0.93 |
| Multiple sites | 49 | 39 | 88 | 40.93 |
| Total | 115 | 100 | 215 | 100.00 |




Breast Cancer ICD-0: C50

Trend of new breast cancer patients in Lampang Cancer Hospital 20 years (since 2005 - 2024)




Number of new breast cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group | Age group Male Female | | Botl | ı sex | | |
|-----------|-----------------------|-----|------|-------|-----|-------|
| (Year) | N | % | N | % | N | % |
| 20-24 | 0 | 0.0 | 2 | 0.2 | 2 | 0.2 |
| 25-29 | 0 | 0.0 | 4 | 0.5 | 4 | 0.5 |
| 30-34 | 0 | 0.0 | 17 | 2.1 | 17 | 2.1 |
| 35-39 | 0 | 0.0 | 39 | 4.8 | 39 | 4.8 |
| 40-44 | 0 | 0.0 | 64 | 7.9 | 64 | 7.9 |
| 45-49 | 0 | 0.0 | 107 | 13.2 | 107 | 13.2 |
| 50-54 | 1 | 0.1 | 123 | 15.2 | 124 | 15.3 |
| 55-59 | 2 | 0.2 | 141 | 17.4 | 143 | 17.7 |
| 60-64 | 0 | 0.0 | 112 | 13.8 | 112 | 13.8 |
| 65-69 | 0 | 0.0 | 98 | 12.1 | 98 | 12.1 |
| 70-74 | 0 | 0.0 | 63 | 7.8 | 63 | 7.8 |
| 75-79 | 0 | 0.0 | 25 | 3.1 | 25 | 3.1 |
| 80-84 | 1 | 0.1 | 9 | 1.1 | 10 | 1.2 |
| 85+ | 0 | 0.0 | 2 | 0.2 | 2 | 0.2 |
| Total | 4 | 0.5 | 806 | 99.5 | 810 | 100.0 |



Type of diagnosis of new breast cancer patients in Lampang Cancer Hospital, 2024


| Type of Diagnosis | Male | Female | Total | % |
|-------------------------|------|--------|-------|--------|
| Clinical investigation | 0 | 1 | 1 | 0.12 |
| Cytology and hematology | 0 | 1 | 1 | 0.12 |
| Histology of metastasis | 0 | 5 | 5 | 0.62 |
| Histology of primary | 4 | 799 | 803 | 99.14 |
| Total | 4 | 806 | 810 | 100.00 |



Treatment of new breast cancer patients in Lampang Cancer Hospital, 2024


| Type of treatment | Male | Female | Total | % |
|-------------------------------------|------|--------|-------|-------|
| Surgery | 0 | 32 | 32 | 3.95 |
| Radiotherapy | 2 | 337 | 339 | 41.85 |
| Systemic therapy | | | | |
| Chemotherapy | 0 | 37 | 37 | 4.57 |
| Targetd Therapy | 0 | 4 | 4 | 0.49 |
| Hormone | 0 | 5 | 5 | 0.62 |
| Palliative care | 0 | 1 | 1 | 0.12 |
| Consult/Investigation | | | | |
| Investigation | 2 | 409 | 411 | 50.74 |
| Consult | 0 | 22 | 22 | 2.72 |






Staging of new breast cancer patients in Lampang Cancer Hospital, 2024


| Staging | Male | Female | Total | % |
|---------------|------|--------|-------|--------|
| Stage IA | 1 | 79 | 80 | 9.88 |
| Stage IIA | 1 | 169 | 170 | 20.99 |
| Stage IIB | 0 | 168 | 168 | 20.74 |
| Stage IIIA | 0 | 146 | 146 | 18.02 |
| Stage IIIB | 0 | 53 | 53 | 6.54 |
| Stage IIIC | 0 | 53 | 53 | 6.54 |
| Stage IVA | 0 | 5 | 5 | 0.62 |
| Stage IVB | 1 | 110 | 111 | 13.70 |
| Unknown Stage | 1 | 23 | 24 | 2.96 |
| Total | 4 | 806 | 810 | 100.00 |



Comparison number of new breast cancer patients in Lampang Cancer Hospital by staging since 2015 - 2024




Extension of new breast cancer patients in Lampang Cancer Hospital, 2024




Metastasis sites of new breast cancer patients in Lampang Cancer Hospital, 2024

| Extension | Male | Female | Total | % |
|--------------------|------|--------|-------|--------|
| Distant lymph node | 0 | 44 | 44 | 40.00 |
| Bone | 1 | 30 | 31 | 28.18 |
| Liver | 0 | 4 | 4 | 3.64 |
| Lung/Pleura | 0 | 7 | 7 | 6.36 |
| Brain | 0 | 2 | 2 | 1.82 |
| Other | 0 | 1 | 1 | 0.91 |
| Multiple sites | 0 | 21 | 21 | 19.09 |
| Total | 1 | 109 | 110 | 100.00 |




Cervical Cancer ICD-0: C53

Trend of new cervical cancer patients in Lampang Cancer Hospital 20 years (since 2005 - 2024)




Number of new cervical cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group | Female | | |
|-----------|--------|--------|--|
| (Year) | N | % | |
| 25-29 | 6 | 2.60 | |
| 30-34 | 14 | 6.06 | |
| 35-39 | 23 | 9.96 | |
| 40-44 | 29 | 12.55 | |
| 45-49 | 27 | 11.69 | |
| 50-54 | 44 | 19.05 | |
| 55-59 | 30 | 12.99 | |
| 60-64 | 24 | 10.39 | |
| 65-69 | 9 | 3.90 | |
| 70-74 | 16 | 6.93 | |
| 75-79 | 4 | 1.73 | |
| 80-84 | 3 | 1.30 | |
| 85+ | 2 | 0.87 | |
| Total | 231 | 100.00 | |



Type of diagnosis of new cervical cancer patients in Lampang Cancer Hospital, 2024


| Type of Diagnosis | Total | % |
|-------------------------|-------|------|
| Histology of metastasis | 3 | 1.3 |
| Histology of primary | 228 | 98.7 |
| Total | 231 | 100 |



Treatment of new cervical cancer patients in Lampang Cancer Hospital, 2024


| Type of treatment | Total | % |
|-----------------------------------|-------|-------|
| Surgery | 2 | 0.87 |
| Radiotherapy | 123 | 53.25 |
| Systemic therapy | | |
| Chemotherapy | 4 | 1.73 |
| Concurrent RT | 146 | 63.20 |
| Consult/Investigation | | |
| Investigation | 1 | 0.43 |
| Consult | 13 | 5.63 |

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan




Staging of new cervical cancer patients in Lampang Cancer Hospital, 2024


| Staging | Total | % |
|------------|-------|--------|
| Stage IA | 1 | 0.43 |
| Stage IB | 35 | 15.15 |
| Stage IC | 1 | 0.43 |
| Stage IIA | 26 | 11.26 |
| Stage IIB | 49 | 21.21 |
| Stage IIIA | 5 | 2.16 |
| Stage IIIB | 32 | 13.85 |
| Stage IIIC | 51 | 22.08 |
| Stage IVA | 6 | 2.60 |
| Stage IVB | 23 | 9.96 |
| Not known | 2 | 0.87 |
| Total | 231 | 100.00 |




Comparison number of new cervical cancer patients in Lampang Cancer Hospital by staging since 2015 - 2024




Extension of new cervical cancer patients in Lampang Cancer Hospital, 2024






Metastasis sites of new cervical cancer patients in Lampang Cancer Hospital, 2024

| Extension | Total | % |
|--------------------|-------|--------|
| Distant lymph node | 4 | 17.39 |
| Bone | 3 | 13.04 |
| Liver | 1 | 4.35 |
| Lung/Pleura | 5 | 21.74 |
| Brain | 2 | 8.70 |
| Multiple sites | 6 | 26.09 |
| Other | 2 | 8.70 |
| Total | 23 | 100.00 |




Thyroid Cancer ICD-O: C73

Trend of new thyroid cancer patients in Lampang Cancer Hospital 20 years (since 2015 - 2024)




Number of new thyroid cancer patients in Lampang Cancer Hospital by age and sex. 2024

| Age group | N | 1ale | Fen | nale | Bot | th sex |
|-----------|----|-------|-----|-------|-----|--------|
| (Year) | N | % | N | % | N | % |
| 10-14 | 1 | 0.60 | 0 | 0.00 | 1 | 0.60 |
| 15-19 | 0 | 0.00 | 3 | 1.79 | 3 | 1.79 |
| 20-24 | 1 | 0.60 | 4 | 2.38 | 5 | 2.98 |
| 25-29 | 1 | 0.60 | 8 | 4.76 | 9 | 5.36 |
| 30-34 | 1 | 0.60 | 16 | 9.52 | 17 | 10.12 |
| 35-39 | 4 | 2.38 | 15 | 8.93 | 19 | 11.31 |
| 40-44 | 1 | 0.60 | 12 | 7.14 | 13 | 7.74 |
| 45-49 | 0 | 0.00 | 17 | 10.12 | 17 | 10.12 |
| 50-54 | 2 | 1.19 | 13 | 7.74 | 15 | 8.93 |
| 55-59 | 6 | 3.57 | 15 | 8.93 | 21 | 12.50 |
| 60-64 | 3 | 1.79 | 14 | 8.33 | 17 | 10.12 |
| 65-69 | 3 | 1.79 | 11 | 6.55 | 14 | 8.33 |
| 70-74 | 5 | 2.98 | 5 | 2.98 | 10 | 5.95 |
| 75-79 | 2 | 1.19 | 4 | 2.38 | 6 | 3.57 |
| 80-84 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 85+ | 0 | 0.00 | 1 | 0.60 | 1 | 0.60 |
| Total | 30 | 17.86 | 138 | 82.14 | 168 | 100.00 |



Type of diagnosis of new thyroid cancer patients in Lampang Cancer Hospital, 2024


| Type of Diagnosis | Male | Female | Total | % |
|-----------------------------------|------|--------|-------|--------|
| Clinical investigation | 0 | 1 | 1 | 0.60 |
| Surgery/autopsy without histology | 0 | 1 | 1 | 0.60 |
| Cytology and hematology | 0 | 3 | 3 | 1.79 |
| Histology of metastasis | 2 | 7 | 9 | 5.36 |
| Histology of primary | 28 | 126 | 154 | 91.67 |
| Total | 30 | 138 | 168 | 100.00 |



Treatment of new thyroid cancer patients in Lampang Cancer Hospital, 2024


| Type of treatment | Male | Female | Total | % |
|-------------------|------|--------|-------|-------|
| Radiotherapy | 1 | 2 | 3 | 1.79 |
| Concurrent RT | 0 | 1 | 1 | 0.60 |
| I131 | 28 | 131 | 159 | 94.64 |
| Consult | 0 | 4 | 4 | 2.38 |

Note: Investigation = CT/Bone Scan/Ultrasound/Mammogram/Total body scan





Staging of new thyroid cancer patients in Lampang Cancer Hospital, 2024

| | | | | U |
|---------------|------|--------|-------|--------|
| Staging | Male | Female | Total | % |
| Stage I | 7 | 59 | 66 | 39.29 |
| Stage II | 4 | 13 | 17 | 10.12 |
| Stage III | 2 | 4 | 6 | 3.57 |
| Stage IV | 16 | 52 | 68 | 40.48 |
| Unknown Stage | 1 | 10 | 11 | 6.55 |
| Total | 30 | 138 | 168 | 100.00 |




Extension of new thyroid cancer patients in Lampang Cancer Hospital, 2024





Metastasis sites of new thyroid cancer patients in Lampang Cancer Hospital, 2024

| | Extension | Male | Female | Total | % |
|---|--------------------|------|--------|-------|--------|
| | Distant lymph node | 6 | 26 | 32 | 52.46 |
| | Bone | 2 | 3 | 5 | 8.20 |
| | Liver | 0 | 1 | 1 | 1.64 |
| | Lung/Pleura | 1 | 5 | 6 | 9.84 |
| 0 | Multiple sites | 4 | 13 | 17 | 27.87 |
| | Total | 13 | 48 | 61 | 100.00 |
| | | | | | |



Number of new cancer by age and sex in Lampang Cancer Hospital (Male), 2024

| Site | ALL AGE | 0- -4 | 5- -9 | 10- -14 | 15- -19 | 20- -24 | 25- -29 | 30- -34 | 35- -39 | 40- -44 | 45- -49 | 50- -54 | 55- -59 | 60- -64 | 65- -69 | 70- -74 | 75- -79 | 80- -84 | 85+ | % of Total | ICD (10th) | | |
|-----------------------------------|------------|----------|----------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|---------------|---------------|--|--|
| Lip | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C00 | | |
| Tongue | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 4 | 2 | 1 | 0 | 0 | 1 | 1.5 | C01-02 | | |
| Mouth | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 3 | 2 | 1 | 2 | 0 | 1.7 | C03-06 | | |
| Salivary glands | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 2 | 1 | 0 | 0.9 | C07-08 | | |
| Tonsil | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 5 | 4 | 3 | 1 | 1 | 0 | 0 | 0 | 1.8 | C09 | | |
| Other oropharynx | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0.8 | C10 | | |
| Nasopharynx | 37 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | 3 | 2 | 6 | 11 | 4 | 1 | 0 | 1 | 1 | 3.9 | C11 | | |
| Hypopharynx | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 3 | 3 | 2 | 2 | 2 | 1 | 0 | 0 | 1.6 | C12-13 | | |
| Oesophagus | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 5 | 10 | 10 | 4 | 1 | 0 | 1 | 1 | 3.7 | C15 | | |
| Stomach | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 3 | 4 | 3 | 2 | 1 | 0 | 0 | 1.8 | C16 | | |
| Colon | 32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 4 | 6 | 8 | 5 | 2 | 0 | 1 | 3.4 | C18 | | |
| Rectum | 121 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 5 | 13 | 17 | 19 | 26 | 20 | 9 | 5 | 2 | 12.7 | C19-20 | | |
| Anus | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0.6 | C21 | | |
| Liver and bile duct | 64 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 4 | 11 | 23 | 9 | 9 | 4 | 0 | 0 | 6.7 | C22,C24 | | |
| Gallbladder | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.1 | C22,C24 | | |
| Pancreas | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0.5 | C25 | | |
| Nose, sinuses etc. | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0.2 | C30-31 | | |
| Larynx | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 4 | 7 | 4 | 2 | 2 | 0 | 1 | 2.7 | C32 | | |
| Trachea, Bronchus and lung | 153 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 7 | 15 | 15 | 42 | 29 | 29 | 9 | 3 | 1 | 16.0 | C32-34 | | |
| Other thoracic organs | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0.3 | C37-38 | | |
| Bone | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0.2 | C40-C41 | | |
| Melanoma of skin | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0.2 | C40-C41 | | |
| Other skin | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 2 | 0 | 6 | 2 | 3 | 2 | 1.9 | C43 | | |
| Connective tissue | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0.4 | C47,C49 | | |
| Breast | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0.4 | C47,C49 | | |
| Vulva | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.4 | C50 | | |
| | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C52 | | |
| Vagina Cervix uteri | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C52 | | |
| | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C54 | | |
| Corpus uteri | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C54 | | |
| Ovary Other female genital organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C57 | | |
| Placenta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C57 | | |
| Penis | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | C60 | | |
| | 240 | 0 | _ | _ | 0 | _ | _ | 0 | 0 | 0 | _ | 7 | | 25 | 58 | | | | 7 | 25.1 | C61 | | |
| Prostate | 6 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 11 0 | 0 | 0 | 62 0 | 57 0 | 13 | 0 | 0.6 | C62 | | |
| Testis Kidney | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 3 | 1 | 0 | 0 | 0.8 | C62 | | |
| Ureter | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0.8 | C66 | | |
| Bladder | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 4 | 3 | 0 | 1.6 | C67 | | |
| | | | 0 | | | | | | | | | | | | | | | | 0 | | C70-72 | | |
| Brain, nervous system | 5 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | | 0.5 | | | |
| Thyroid | 30 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 4 | 1 | 0 | 2 | 6 | 3 | 3 | 5 | 2 | 0 | 0 | 3.1 | C73 | | |
| Adrenal gland Other endocrine | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C74 | | |
| | 3 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | C75 | | |
| Hodgkin disease | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C81 | | |
| Non-Hodgkin lymphoma | 24 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 3 | 1 | 5 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 2.5 | C82-85,C96 | | |
| Multiple myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C90 | | |
| Lymphoid leukemia | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.1 | C91 | | |
| Other and unspecified | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.2 | O&U | | |
| All sites | 955 | 1 | 2 | 3 | 5 | 4 | 4 | 7 | 16 | 22 | 28 | 83 | 111 | 182 | 170 | 164 | 100 | 35 | 18 | 100.0 | ALL | | |

Number of new cancer by age and sex in Lampang Cancer Hospital (Female), 2024

| | ALL | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ | % of | ICD |
|-----------------------------|------|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|------------|
| Site | AGE | -4 | -9 | -14 | -19 | -24 | -29 | -34 | -39 | -44 | -49 | -54 | -59 | -64 | -69 | -74 | -79 | -84 | | Total | (10th) |
| Lip | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.1 | C00 |
| Tongue | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0.4 | C01-02 |
| Mouth | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0.7 | C03-06 |
| Salivary glands | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C07-08 |
| Tonsil | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0.1 | C09 |
| Other oropharynx | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C10 |
| Nasopharynx | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 4 | 3 | 4 | 0 | 1 | 1 | 0 | 0 | 0 | 1.2 | C11 |
| Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C12-13 |
| Oesophagus | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 0.5 | C15 |
| Stomach | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 | 2 | 0 | 1 | 0 | 0 | 0.6 | C16 |
| Colon | 17 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 5 | 1 | 0 | 0 | 1 | C18 |
| Rectum | 92 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 2 | 5 | 9 | 20 | 22 | 16 | 7 | 3 | 3 | 1 | 5.4 | C19-20 |
| Anus | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 0 | 0 | 0.7 | C21 |
| Liver and bile duct | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 5 | 7 | 6 | 0 | 0 | 0 | 1.3 | C22,C24 |
| Gallbladder | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0.2 | C23 |
| Pancreas | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0.2 | C25 |
| Nose, sinuses etc. | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0.2 | C30-31 |
| Larynx | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0.3 | C32 |
| Trachea, Bronchus and lung | 128 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 5 | 14 | 25 | 24 | 19 | 24 | 10 | 2 | 0 | 7.5 | C33-34 |
| Other thoracic organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C37-38 |
| Bone | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C40-C41 |
| Melanoma of skin | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0.3 | C43 |
| Other skin | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 4 | 0 | 3 | 0.6 | C44 |
| Connective tissue | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0.4 | C47,C49 |
| Breast | 806 | 0 | 0 | 0 | 0 | 2 | 4 | 17 | 39 | 64 | 107 | 123 | 141 | 112 | 98 | 63 | 25 | 9 | 2 | 47.1 | C50 |
| Vulva | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 0.4 | C51 |
| Vagina | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0.2 | C52 |
| Cervix uteri | 231 | 0 | 0 | 0 | 0 | 0 | 6 | 14 | 23 | 29 | 27 | 44 | 30 | 24 | 9 | 16 | 4 | 3 | 2 | 13.5 | C53 |
| Corpus uteri | 105 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 23 | 32 | 24 | 10 | 8 | 3 | 0 | 6.1 | C54 |
| Ovary | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0.5 | C56 |
| Other female genital organs | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C57 |
| Placenta | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C58 |
| Penis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C60 |
| Prostate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C61 |
| Testis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C62 |
| Kidney | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0.1 | C64 |
| Ureter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C66 |
| Bladder | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0.2 | C67 |
| Brain, nervous system | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0.2 | C70-72 |
| Thyroid | 138 | 0 | 0 | 0 | 3 | 4 | 8 | 16 | 15 | 12 | 17 | 13 | 15 | 14 | 11 | 5 | 4 | 0 | 1 | 8.1 | C73 |
| Adrenal gland | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | C74 |
| Other endocrine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C75 |
| Hodgkin disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C81 |
| Non-Hodgkin lymphoma | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 4 | 2 | 3 | 0 | 0 | 0 | 1.1 | C82-85,C96 |
| Multiple myeloma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.1 | C90 |
| Lymphoid leukemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C91 |
| Other and unspecified | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0.3 | O&U |
| All sites | 1712 | 0 | 0 | 0 | 3 | 7 | 22 | 51 | 87 | 121 | 173 | 231 | 287 | 260 | 210 | 152 | 69 | 27 | 12 | 100.0 | ALL |

Pathology according to site and sex. 2024

| Pathology and Sites | Male | Female | Total |
|--|------|--------|-------|
| Total | 995 | 1,712 | 2,667 |
| COO LIP | 1 | 1 | 2 |
| 8070: Squamous cell carcinoma, NOS | 1 | 1 | 2 |
| C01 BASE OF TONGUE | 1 | 1 | 2 |
| 8070: Squamous cell carcinoma, NOS | 1 | 1 | 2 |
| CO2 OTHER AND UNSPECIFIED PARTS OF TONGUE | 13 | 5 | 18 |
| 8070: Squamous cell carcinoma, NOS | 13 | 5 | 18 |
| CO3 GUM | 4 | 5 | 9 |
| 8070: Squamous cell carcinoma, NOS | 3 | 4 | 7 |
| 8071 : Squamous cell carcinoma, keratinizing, NOS | 1 | 1 | 2 |
| C04 FLOOR OF MOUTH | 4 | 1 | 5 |
| 8070: Squamous cell carcinoma, NOS | 2 | 0 | 2 |
| 8200 :Adenoid cystic carcinoma | 1 | 1 | 2 |
| 8083 : Basaloid squamous cell carcinoma | 1 | 0 | 1 |
| CO5 PALATE | 4 | 2 | 6 |
| 8070: Squamous cell carcinoma, NOS | 4 | 1 | 5 |
| 8200 : Adenoid cystic carcinoma | 0 | 1 | 1 |
| C06 OTHER AND UNSPECIFIED PARTS OF MOUTH | 4 | 4 | 8 |
| 8070: Squamous cell carcinoma, NOS | 3 | 4 | 7 |
| 8260 : Papillary adenocarcinoma, NOS | 1 | 0 | 1 |
| C07 PAROTID GLANID | 6 | 2 | 8 |
| 8010 : Carcinoma, NOS | 0 | 1 | 1 |
| 8070 : Squamous cell carcinoma, NOS | 1 | 0 | 1 |
| 8082 : Lymphoepithelial carcinoma | 1 | 0 | 1 |
| 8140 : Adenocarcinoma, NOS | 3 | 0 | 3 |
| 8200 : Adenoid cystic carcinoma | 0 | 1 | 1 |
| 8430 : Mucoepidermoid carcinoma | 1 | 0 | 1 |
| C08 OTHER AND UNSPECIFIED MAJOR SALIVARY GLANDS | 3 | 0 | 3 |
| 8430 : Mucoepidermoid carcinoma | 2 | 0 | 2 |
| 8500 : duct carcinoma, NOS | 1 | 0 | 1 |
| C09 TONSIL | 17 | 2 | 19 |
| 8070: Squamous cell carcinoma, NOS | 17 | 2 | 19 |
| C10 OROPHARYNX | 8 | 1 | 9 |
| 8070: Squamous cell carcinoma, NOS | 8 | 1 | 9 |
| C11 NASOPHARYNX | 37 | 20 | 57 |
| 8010: Carcinoma, NOS | 2 | 2 | 4 |
| 8020: Carcinoma, undifferentiated type, NOS | 3 | 5 | 8 |
| 8070: Squamous cell carcinoma, NOS | 2 | 1 | 3 |
| 8072: Squamous cell carcinoma, large cell, nonkeratinzing, NOS | 30 | 12 | 42 |
| C12 PYRIFORM SINUS | 9 | 0 | 9 |
| 8070: Squamous cell carcinoma, NOS | 9 | 0 | 9 |
| C13 HYPOPHARYNX | 6 | 0 | 6 |
| 8070: Squamous cell carcinoma, NOS | 6 | 0 | 6 |
| · | | _ | |

| Pathology and Sites | Male | Female | Total |
|--|------|--------|-------|
| C15 ESOPHAGUS | 35 | 8 | 43 |
| 8000: No histological proof | 0 | 1 | 1 |
| 8010: Carcinoma, NOS | 0 | 1 | 1 |
| 8070: Squamous cell carcinoma, NOS | 32 | 6 | 38 |
| 8140: Adenocarcinoma, NOS | 3 | 0 | 3 |
| C16 STOMACH | 17 | 11 | 28 |
| 8013 : Large cell neuroendocrine carcinoma | 1 | 0 | 1 |
| 8140 : Adenocarcinoma, NOS | 6 | 7 | 13 |
| 8145 : Adenocarcinoma, deffuse type | 3 | 0 | 3 |
| 8260 : Papillary adenocarcinoma, NOS | 1 | 0 | 1 |
| 8480 : Mucinous adenocarcinoma | 1 | 0 | 1 |
| 8490 : Signet ring cell carcinoma | 4 | 4 | 8 |
| 8550 : Acinic cell adenocarcinoma | 1 | 0 | 1 |
| C18 COLON | 32 | 17 | 49 |
| 8000 : No histological proof | 2 | 1 | 3 |
| 8140 : Adenocarcinoma, NOS | 25 | 16 | 41 |
| 8480 : Mucinous adenocarcinoma | 3 | 0 | 3 |
| 8481 : Mucin-producing adenocarcinoma | 2 | 0 | 2 |
| C19 RECTOSIGMOID JUNCTION | 7 | 4 | 11 |
| 8140: Adenocarcinoma, NOS | 6 | 4 | 10 |
| 8490 : Signet ring cell carcinoma | 1 | 0 | 1 |
| C20 RECTUM | 114 | 88 | 202 |
| 8000: No histological proof | 0 | 1 | 0 |
| 8140: Adenocarcinoma, NOS | 111 | 0 | 1 |
| 8481: Mucin-producing adenocarcinoma | 2 | 85 | 195 |
| 8263 : Adenocarcinoma in tubulovillous adenoma | 1 | 2 | 4 |
| C21 ANUS AND ANAL CANAL | 6 | 12 | 18 |
| 8070 : Squamous cell carcinoma, NOS | 1 | 7 | 8 |
| 8140 : Adenocarcinoma, NOS | 4 | 5 | 10 |
| 8480 : Mucinous adenocarcinoma | 1 | 0 | 1 |
| C22 LIVER AND INTRAHEPATIC BILE DUCTS | 62 | 22 | 84 |
| 8000 : No histological proof | 32 | 9 | 42 |
| 8010 : Carcinoma, NOS | 2 | 1 | 4 |
| 8140 : Adenocarcinoma, NOS | 11 | 5 | 17 |
| 8144 : Adenocarcinoma, intestinal type | 0 | 1 | 1 |
| 8160 : Cholangiocarcinoma | 7 | 4 | 11 |
| 8170 : Hepatocellular carcinoma, NOS | 9 | 1 | 10 |
| 8249 : Neuroendocrine tumor, grade 2 | 0 | 1 | 1 |
| 8970 : Hepatoblastoma | 1 | 0 | 1 |
| C23 GALLBLADDER | 1 | 3 | 4 |
| 8140 : Adenocarcinoma, NOS | 1 | 2 | 3 |
| 8480 : Mucinous adenocarcinoma | 0 | 1 | 1 |

| Pathology and Sites | Male | Female | Total |
|--|------|--------|-------|
| C24 OTHER AND UNSPECIFIED PARTS OF BILIARY TRACT | 2 | 0 | 2 |
| 8000 : No histological proof | 1 | 0 | 1 |
| 8140 : Adenocarcinoma, NOS | 1 | 0 | 1 |
| C25 PANCREAS | 5 | 4 | 9 |
| 8000: No histological proof | 2 | 1 | 3 |
| 8140: Adenocarcinoma, NOS | 2 | 1 | 3 |
| 8211:Tubular carcinoma | 1 | 0 | 1 |
| 8500 : Infiltrating duct carcinoma, NOS | 0 | 2 | 2 |
| C30 NASAL CAVITY AND MIDDLE EAR | 1 | 3 | 4 |
| 8070 : Squamous cell carcinoma, NOS | 0 | 2 | 2 |
| 8720 : Malignant melanoma | 1 | 0 | 1 |
| 9522 : Esthesioneuroblastoma | 0 | 1 | 1 |
| C31 ACCESSORY SINUSES | 1 | 0 | 1 |
| 8072 : Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 1 | 0 | 1 |
| C32 LARYNX | 26 | 5 | 31 |
| 8000 : No histological proof | 1 | 1 | 2 |
| 8032 : Spindle cell carcinoma,NOS | 1 | 0 | 1 |
| 8070 : Squamous cell carcinoma, NOS | 21 | 4 | 25 |
| 8071 : Squamous cell carcinoma, keratinizing, NOS | 3 | 0 | 3 |
| C34 BRONCHUS AND LUNG | 153 | 128 | 281 |
| 8000: No histological proof | 13 | 19 | 32 |
| 8010: Carcinoma, NOS | 5 | 5 | 10 |
| 8012: Large cell carcinoma, NOS | 1 | 0 | 1 |
| 8013: Large cell neuroendocrine carcinoma | 1 | 0 | 1 |
| 8041: Small cell carcinoma, NOS | 6 | 2 | 8 |
| 8046: Non-small cell carcinoma | 20 | 21 | 41 |
| 8070: Squamous cell carcinoma, NOS | 21 | 4 | 25 |
| 8140 : Adenocarcinoma, NOS | 76 | 62 | 138 |
| 8246 : Neuroendocrine carcinoma, NOS | 1 | 0 | 1 |
| 8260 : Papillary adenocarcinoma, NOS | 1 | 5 | 6 |
| 8430 : Mucoepidermoid carcinoma | 1 | 0 | 1 |
| 8480 : Mucinous adenocarcinoma | 2 | 2 | 4 |
| 8481 : Mucin-producing adenocarcinoma | 1 | 0 | 1 |
| 8550 : Acinic cell adenocarcinoma | 4 | 7 | 11 |
| 8560 : Adenosquamous carcinoma | 0 | 1 | 1 |
| C37 THYMUS | 3 | 0 | 3 |
| 8583 : Thymoma, type B1, NOS | 1 | 0 | 1 |
| 8586 : Thymic carcinoma, NOS | 2 | 0 | 2 |
| C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES | 2 | 2 | 4 |
| 9040 : Synovioma, malignant | 1 | 0 | 1 |
| 9220 : Chondrosarcoma, NOS | 1 | 0 | 1 |
| 9240 : Mesenchymal chondrosarcoma | 0 | 1 | 1 |
| 9370 : Chordoma, NOS | 0 | 1 | 1 |
| • | - | | • |

| Pathology and Sites | Male | Female | Total |
|---|------|--------|-------|
| C42 HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS | 1 | 1 | 2 |
| 9731 : Plasmacytoma, NOS | 0 | 1 | 1 |
| 9823: Chronic lymphocytic leukemia | 1 | 0 | 1 |
| C44 SKIN | 22 | 16 | 38 |
| 8720 : Malignant melanoma | 4 | 5 | 9 |
| 8070 : Squamous cell carcinoma, NOS | 12 | 9 | 20 |
| 8090 : Basal cell carcinoma,NOS | 2 | 0 | 2 |
| 8094 : Basosquamous carcinoma | 1 | 1 | 2 |
| 8097 : Basal cell carcinoma, nodular | 3 | 1 | 4 |
| C47 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM | 0 | 1 | 1 |
| 9540: Malignant peripheral nerve sheath tumor | 0 | 1 | 1 |
| C49 CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES | 4 | 6 | 10 |
| 8000 : No histological proof | 0 | 1 | 1 |
| 8802 : Pleomorphic cell sarcoma | 2 | 1 | 3 |
| 8805 : Undifferentiated sarcoma | 1 | 1 | 2 |
| 8806 : Desmoplastic round cell tumor | 1 | 0 | 1 |
| 8811 : Myxofibroma, NOS | 0 | 2 | 2 |
| 8855 : Mixed liposarcoma | 0 | 1 | 1 |
| C50 BREAST | 4 | 806 | 810 |
| 8000 : No histological proof | 0 | 1 | 1 |
| 8010 : Carcinoma, NOS | 0 | 4 | 4 |
| 8050 : Papillary carcinoma, NOS | 1 | 4 | 5 |
| 8076 : Squamous cell carcinoma, microinvasive | 0 | 1 | 1 |
| 8140 : Adenocarcinoma, NOS | 0 | 4 | 4 |
| 8480 : Mucinous adenocarcinoma | 0 | 7 | 7 |
| 8500 : Infiltrating duct carcinoma, NOS | 2 | 753 | 755 |
| 8502 : Secretory carcinoma | 1 | 0 | 1 |
| 8507 : Invasive micropapillary carcinoma | 0 | 1 | 1 |
| 8510 : Medullary carcinoma, NOS | 0 | 1 | 1 |
| 8520 : Invasive lobular carcinoma | 0 | 23 | 23 |
| 8575 : Metaplastic carcinoma,NOS | 0 | 4 | 4 |
| 9020 : Phyllodes tumor,malignant | 0 | 2 | 2 |
| 9120 : Hemangiosarcoma | 0 | 1 | 1 |
| C51 VULVA | 0 | 7 | 7 |
| 8070 : Squamous cell carcinoma, NOS | 0 | 6 | 6 |
| 8071 : Squamous cell carcinoma, keratinizing, NOS | 0 | 1 | 1 |
| C52 VAGINA | 0 | 4 | 4 |
| 8070 : Squamous cell carcinoma, NOS | 0 | 4 | 4 |

| Pathology and Sites | Male | Female | |
|--|------|---------------|-----|
| C53 CERVIX UTERI | 0 | 231 | 231 |
| 8001 : Tumor cell, malignant | 0 | 1 | 1 |
| 8041: Small cell neuroendocrine carcinoma | 0 | 4 | 4 |
| 8045 : Combined small cell-adenocarcinoma | 0 | 1 | 1 |
| 8052 : Papillary squamous cell carcinoma | 0 | 1 | 1 |
| 8070: Squamous cell carcinoma, NOS | 0 | 179 | 179 |
| 8071: Squamous cell carcinoma, keratinizing, NOS | 0 | 1 | 1 |
| 8072: Squamous cell carcinoma, large cell, nonkeratinzing, NOS | 0 | 5 | 5 |
| 8076 : Squamous cell carcinoma, microinvasive | 0 | 1 | 1 |
| 8140: Adenocarcinoma, NOS | 0 | 21 | 21 |
| 8246 : Neuroendocrine carcinoma, NOS | 0 | 1 | 1 |
| 8310 : Clear cell adenocarcinoma, NOS | 0 | 1 | 1 |
| 8384: Adenocarcinoma, endocervical type | 0 | 8 | 8 |
| 8481 : Mucin-producing adenocarcinoma | 0 | 1 | 1 |
| 8482 : Endoecrvical adenocarcinoma | 0 | 2 | 2 |
| 8560: Adenosquamous carcinoma | 0 | 4 | 4 |
| C54 CORPUS UTERI | 0 | 105 | 105 |
| 8140: Adenocarcinoma, NOS | 0 | 2 | 2 |
| 8310: Clear cell adenocarcinoma, NOS | 0 | 4 | 4 |
| 8380: Endometrioid carcinoma | 0 | 86 | 86 |
| 8441: Serous cystadenocarcinoma, NOS | 0 | 6 | 6 |
| 8481: Mucin-producing adenocarcinoma | 0 | 1 | 1 |
| 8910: Embryonal rhabdomayosarcoma, NOS | 0 | 1 | 1 |
| 8980: Carcinosarcoma, NOS | 0 | 5 | 5 |
| C56 OVARY | 0 | 9 | 9 |
| 8000: No histological proof | 0 | 2 | 2 |
| 8310: Clear cell adenocarcinoma, NOS | 0 | 2 | 2 |
| 8441: Serous cystadenocarcinoma, NOS | 0 | 5 | 5 |
| C57 OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS | 0 | 5 1 | 1 |
| 8441: Serous cystadenocarcinoma, NOS | 0 | 1 | 1 |
| C58 PLACENTA | 0 | 1 | 1 |
| | 0 | 1 | 1 |
| 9100 : Choriocarcinoma, NOS C60 PENIS | | | • |
| | 3 | 0 | 3 |
| 8070: Squamous cell carcinoma, NOS | 3 | 0 | 3 |
| C61 PROSTATE GLAND | 240 | 0 | 240 |
| 8000: No histological proof | 3 | 0 | 3 |
| 8010: Carcinoma, NOS | 1 | 0 | 1 |
| 8140: Adenocarcinoma, NOS | 148 | 0 | 148 |
| 8550: Acinar cell carcinoma | 88 | 0 | 88 |
| C62 TESTIS | 6 | 0 | 6 |
| 8000: No histological proof | 1 | 0 | 1 |
| 9061: Seminoma, NOS | 2 | 0 | 2 |
| 9064: Germinoma | 2 | 0 | 2 |
| 9085: Mixed germ cell tumor | 1 | 0 | 1 |

| Pathology and Sites | Male | Female | Total |
|---|------|--------|-------|
| C64 KIDNEY | 8 | 2 | 10 |
| 8000 : No histological proof | 1 | 0 | 1 |
| 8070 : Squamous cell carcinoma, NOS | 1 | 0 | 1 |
| 8260 : Papillary adenocarcinoma, NOS | 0 | 1 | 1 |
| 8310 : Clear cell adenocarcinoma, NOS | 1 | 0 | 1 |
| 8312 : Renal cell carcinoma,NOS | 4 | 1 | 5 |
| 8480 : Mucinous adenocarcinoma | 1 | 0 | 1 |
| C66 Ureter | 2 | 0 | 2 |
| 8120: Urothelial carcinoma, NOS | 1 | 0 | 1 |
| 8130: Papillary transitional cell carcinoma | 1 | 0 | 1 |
| C67 BLADDER | 15 | 4 | 19 |
| 8070: Squamous cell carcinoma, NOS | 1 | 0 | 1 |
| 8071:Squamous cell carcinoma, keratinizing, NOS | 1 | 0 | 1 |
| 8120 : Infiltrating urothelial carcinoma | 7 | 4 | 11 |
| 8130: Papillary urothelial carcinoma | 6 | 0 | 6 |
| C71 BRAIN | 5 | 4 | 9 |
| 9380: Glioma, malignant | 0 | 1 | 1 |
| 9440: Glioblastoma, NOS | 3 | 3 | 6 |
| 9450: Oligodendroglioma | 2 | 0 | 2 |
| C73 THYROID GLAND | 30 | 138 | 168 |
| 8000: No histological proof | 0 | 2 | 2 |
| 8010: Carcinoma, NOS | 3 | 0 | 3 |
| 8021 : Carcinoma, anaplastic, NOS | 0 | 2 | 2 |
| 8260: Papillary adenocarcinoma, NOS | 16 | 87 | 103 |
| 8290: Oxyphilic adenocarcinoma | 2 | 1 | 3 |
| 8330: Follicular adenocarcinoma, NOS | 7 | 28 | 35 |
| 8335: Follicular carcinoma, minimally invasive | 0 | 5 | 5 |
| 8337: Poorly differentiated thyroid carcinoma | 1 | 0 | 1 |
| 8340: Papillary carcinoma, follicular variant | 1 | 9 | 10 |
| 8341: Papillary microcarcinoma | 0 | 2 | 2 |
| 8343: Papillary carcinoma, encapsulated | 0 | 1 | 1 |
| 8345 : Medullary carcinoma of thyroid | 0 | 1 | 1 |
| C74 ADRENAL GLAND | 1 | 1 | 2 |
| 8700 : Pheochromocytoma, malignant | 0 | 1 | 1 |
| 9500 : Neuroblastoma, NOS | 1 | 0 | 1 |
| C75 OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES | 3 | 0 | 3 |
| 9064 : Germ cell tumor, NOS | 3 | 0 | 3 |

| Pathology and Sites | Male | Female | Total |
|---|------|--------|-------|
| C77 LYMPH NODES | 25 | 19 | 44 |
| 9590 : Malignant lymphoma, NOS | 0 | 1 | 1 |
| 9591 : Malignant lymphoma, non-Hodgkin | 2 | 1 | 3 |
| 9651 : Hodgkin lymphoma | 1 | 0 | 1 |
| 9680 : Diffuse large B-cell lymphoma, NOS | 15 | 17 | 32 |
| 9690 : Follicular lymphoma, NOS | 1 | 0 | 1 |
| 9698 : Follicular lymphoma, grade 3 | 1 | 0 | 1 |
| 9702 : Mature T-cell lymphoma, NOS | 1 | 0 | 1 |
| 9714 : Mature T-cell lymphoma, NOS | 3 | 0 | 3 |
| 9719 : Extranodal NK/T cell lymphoma | 1 | 0 | 1 |
| C80 UNKNOWN PRIMARY SITE | 2 | 5 | 7 |
| 8000: No histological proof | 0 | 3 | 3 |
| 8010: Carcinoma, NOS | 1 | 1 | 2 |
| 8070: Squamous cell carcinoma, NOS | 1 | 0 | 1 |
| 8140: Adenocarcinoma, NOS | 0 | 1 | 1 |

Publications of cancer registry, Lampang Cancer Hospital

Hospital-based Cancer Registration Publications:

- Hospital Based Cancer Registry, LPCH 1999 (Published April 2002)
- Hospital Based Cancer Registry, LPCH 2001 (Published June 2002)
- Hospital Based Cancer Registry, LPCH 2002 (Published April 2003)
- Hospital Based Cancer Registry, LPCH 2003 (Published June 2004)
- Hospital Based Cancer Registry, LPCH 2004 (Published June 2005)
- Hospital Based Cancer Registry, LPCH 2005 (Published June 2006)
- Hospital Based Cancer Registry, LPCH 2006 (Published March 2007)
- Hospital Based Cancer Registry, LPCH 2007 (Published July 2008)
- Hospital Based Cancer Registry, LPCH 2008 (Published August 2009)
- Hospital Based Cancer Registry, LPCH 2009 (Published August 2010)
- Hospital Based Cancer Registry, LPCH 2010 (Published August 2011)
- Hospital Based Cancer Registry, LPCH 2011 (Published March 2012)
- Hospital Based Cancer Registry, LPCH 2012 (Published March 2013)
- Hospital Based Cancer Registry, LPCH 2013 (Published February 2014)
- Hospital Based Cancer Registry, LPCH 2014 (Published June 2015)
- Hospital Based Cancer Registry, LPCH 2015 (Published June 2016)
- Hospital Based Cancer Registry, LPCH 2016 (Published June 2017)
- Hospital Based Cancer Registry, LPCH 2017 (Published June 2018)
- Hospital Based Cancer Registry, LPCH 2018 (Published June 2019)
- Hospital Based Cancer Registry, LPCH 2019 (Published May 2020)
- Hospital Based Cancer Registry, LPCH 2020 (Published May 2021)
- Hospital Based Cancer Registry, LPCH 2021 (Published June 2022)
- Hospital Based Cancer Registry, LPCH 2022 (Published May 2023)
- Hospital Based Cancer Registry, LPCH 2023 (Published June 2024)

Population- based Cancer Registration Publications:

- Cancer Incidence in Lampang Vol. II, 1993-1997 (Published January 2002)
- Cancer Mortality in Lampang, 1990-2000 (Published August 2003)
- Cancer Incidence and Mortality in Lampang Vol. III, 1998-2002 (Published July 2004)
- Cancer Survival in Lampang, 1990-2002 (Published November 2005)
- Cancer Incidence in Lamphun, 1998-2002 (Published May 2006)
- Cancer Incidence in Phitsanulok, 1998-2002 (Published September 2006)
- Trends in Cancer Incidence in Lampang, Thailand, 1985-2004 (Published October 2007)
- Cancer Incidence in Northern, Thailand, 2003-2007 (Published October 2009)
- Cancer incidence in Phare, Thailand, 2007-2009 (Published August 2011)
- Trend cancer survival in Lampang, Thailand, 1988-2007 (Published September 2012)
- Cancer incidence in Chiang Rai, Thailand, 2008-2010 (Published October 2013)
- Cancer Incidence in Northern, Thailand, 2008-2012 (Published October 2014)
- Cancer Incidence Trend in Lampang, Thailand, 1988-2012 (Published November 2014)
- Cancer Incidence Trend in Phayao, Thailand, 2010-2012 (Published September 2015)
- Cancer Incidence Trend in Northern Thailand, 1993-2012 (Published December 2015)
- Cancer Survival in Northern Thailand, 2003-2012 (Published August 2016)
- Epidemiology of Liver Cancer in North Thailand (Published September 2017)
- Trends In Cancer Incidence and Mortality in Northern Thailand, 1993-2017 (Published February 2020)
- Cancer epidemiology of an aging population in Upper-Northern Thailand from 2013 to 2017 (Journal of Medicine and Health Sciences Published Vol.28 No.2 August 2021)
- Incidence and Mortality Rates of Cancer in Mae Hong Son Province. (Srinagarind Medical Journal Published Vol.38 No.1 January - February 2023)

Cancer in Thailand Publications:

- Cancer in Thailand vol. II, 1992-1994 (Published 1999)
- Cancer in Thailand vol. III, 1995-1997 (Published 2003)
- Cancer in Thailand vol. IV, 1998-2000 (Published 2007)
- Cancer in Thailand vol. V, 2001-2003 (Published 2009)
- Cancer in Thailand vol. VI, 2004-2006 (Published 2012)
- Cancer in Thailand vol. VII, 2007-2009 (Published 2013)
- Cancer in Thailand vol. VIII, 2010-2012 (Published 2015)
- Cancer in Thailand vol. IX, 2013-2015 (Published 2018)
- Cancer in Thailand vol. X, 2016-2018 (Published 2021)

International Publications:

- Cancer in Five Continents Vol. VIII, 1993-1997 IARC, WHO. Scientific Publications No. 155 (Published 2002)
- Cancer in Five Continents Vol. IX, 1998-2002 IARC, WHO Scientific Publications No. 160 (Published 2007)
- Cancer in Five Continents Vol. X, 2003-2007 IARC, WHO Scientific Publications No. 164 (Published 2013)
- Cancer Survival in Africa, Asia, the Caribbean and Central America, IARC, WHO Scientific Publications No. 162 (Published 2011)
- Lalitwongsa S, Pongnikorn D, Daoprasert K, Sriplung H, Bilheem S. Breast Cancer in Lampang, a Province in Northern Thailand: Analysis of 1993-2012 Incidence Data and Future Trends. Asian Pac J Cancer Prev. 2015;16(18):8327–33.
- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015 Mar 14;385(9972):977–1010.
- Pruksakorn D, Phanphaisarn A, Pongnikorn D, Daoprasert K, Teeyakasem P, Chaiyawat P, et al. AgeStandardized Incidence Rates and Survival of Osteosarcoma in Northern Thailand. Asian Pac J Cancer Prev. 2016;17(7):3455–8.
- Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, CONCORD working group, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017 Feb;144(2):405–13.
- Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C, CONCORD working group, et al. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017 Feb;144(2):396–404.
- Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017 Jun;18(6):719–31.
- Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, CONCORD working group, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89,828 children from 198 registries in 53 countries. Lancet Haematol. 2017;4(5):e202–17.
- Virani S, Bilheem S, Chansaard W, Chitapanarux I, Daoprasert K, Khuanchana S, et al. National and Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with the Highest Burdens. Cancers. 2017;9.

- Sripan P, Sriplung H, Pongnikorn D, Virani S, Bilheem S, Chaisaengkhaum U, et al. Trends in Female Breast Cancer by Age Group in the Chiang Mai Population. Asian Pac J Cancer Prev. 2017 01;18(5):1411–6.
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, CONCORD working group, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 Jan 30;
- Pongnikorn D, Daoprasert K, Waisri N, Laversanne M, Bray F. Cancer incidence in northern Thailand: Results from six population-based cancer registries 1993-2012. Int J Cancer. 2018 May 1;142(9):1767–75.
- Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Est ve, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, CONCORD Working Group* .Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. www.thelancet.com Published online January 30, 2018
- Joanne T. Chang, Jihyoun Jeon, Hutcha Sriplung, Seesai Yeesoonsang, Surichai Bilheem, Laura Rozek, Imjai Chitapanarux, Donsuk Pongnikorn, Karnchana Daoprasert, Patravoot Vatanasapt, Krittika Suwanrungruang, Rafael Meza. Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014. American Society of Clinical Oncology, 2018
- Ilona Argirion, Katie R Zarins, Kali Defever, Krittika Suwanrungruang, Joanne T Chang, Donsuk Pongnikorn, Imjai Chitapanarux, Hutcha Sriplung, Patravoot Vatanasapt, Laura S Rozek. Temporal Changes in Head and Neck Cancer Incidence in Thailand Suggest Changing Oropharyngeal Epidemiology in the Region. Journal of global oncology. 2019;5.
- Serena S Bidwell, Catherine C Peterson, Kathryn Demanelis, Katie R Zarins, Rafael Meza, Hutcha Sriplung, Surapon Wiangnon, Thirachit Chotsampancharoen, Imjai Chitapanarux, Donsuk Pongnikorn, Karnchana Daoprasert, Krittika Suwanrungruang, Wasan Chansaard, Laura S Rozek. Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990-2011. Pediatric blood & cancer. 2019;66(1).

- Donlapark Ponnoprat, Papangkorn Inkeaw, Jeerayut Chaijaruwanich, Patrinee Traisathit, Patumrat Sripan, Nakarin Inmutto, Wittanee Na Chiangmai, Donsuk Pongnikorn, Imjai Chitapanarux. Classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on multi-phase CT scans. Medical & biological engineering & computing. 2020;58(10).
- Donsuk Pongnikorn, Phichayut Phinyo, Jayanton Patumanond, Karnchana Daoprasert, Pachaya Phothong, Boonying Siribumrungwong. Individualized Prediction of Breast Cancer Survival Using Flexible Parametric Survival Modeling: Analysis of a Hospital-Based National Clinical Cancer Registry. Cancers. 2021;13(7).
- Jeerawan Klangjorhor, Donsuk Pongnikorn, Areerak Phanphaisarn, Parunya Chaiyawat, Pimpisa Teeyakasem, Pathacha Suksakit, Arnat Pasena, Sasimol Udomruk, Santhasiri Orrapin, Samatit Pornwattanavate, Narate Waisri, Karnchana Daoprasert, Taweechok Wisanuyotin, Chalongpon Santong, Suleeporn Sangrajrang, et al. An analysis of the incidence and survival rates of bone sarcoma patients in thailand: reports from population-based cancer registries 2001–2015. Cancer Epidemiology. 2022;76.
- Maláková K, Cabasag CJ, Bardot A, Sangrajrang S, Chitapanarux I, Sripan P, et al. Cancer survival in Thailand from 1997 to 2012: Assessing the impact of universal health coverage. J Cancer Policy. 2022;34:100353.
- Sripan P, Rerkasem A, Pongnikorn D, Chitapanarux I, Tangmunkongvorakul A, Ukranun W, et al. Trends in the Incidence of Kaposi's Sarcoma and Non-Hodgkin Lymphoma in Northern Thailand during the Time Period of Universal Access to Antiretroviral Treatment, 1998-2017. Asian Pac J Cancer Prev. 2023;24(3):1055-61.
- Soerjomataram I, Cabasag C, Bardot A, Fidler-Benaoudia MM, Miranda-Filho A, Ferlay J, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol. 2023;24(1):22-32.

Cite

Cancer Registry Unit, Lampang Cancer Hospital.

Hospital Based Cancer Registry,

Lampang Cancer Hospital 2024.

Lampang: Lampang Cancer Hospital, 2025.



Publisher

Lampang Cancer Hospital, Department of Medical Services,
Ministry of Public Health
199, Village 12, Pichai Sub-district, Muang district, Lampang, 52000